Article Details

Harbour BioMed Announces Dosing of First Patient in Phase I Clinical Study of its Next-Generation ...

Retrieved on: 2021-03-22 00:22:30

Tags for this article:

Click the tags to see associated articles and topics

Harbour BioMed Announces Dosing of First Patient in Phase I Clinical Study of its Next-Generation .... View article details on hiswai:

Excerpt

"HBM4003 is a new generation of anti-CTLA-4 antibody. ... Harbour Mice®, which generates fully human monoclonal antibodies in the classical two ...

Article found on: www.prnewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo